Advertisement

Topics

Aerpio Therapeutics, Inc. Company Profile

16:47 EDT 22nd June 2018 | BioPortfolio

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel disease. Aerpio is a leader in the development of small molecule drugs based on Tie2 activation and the stabilization of Hypoxia-inducible Factor 1α (HIF‐1α). The Company’s lead program, AKB‐9778, is a first‐in‐class stabilizer of the Tie2 pathway and is in clinical development for diabetic macular edema. AKB‐4924, a HIF‐1α stabilizer, is in late preclinical development for inflammatory bowel disease. More information is available at www.aerpio.com.


News Articles [795 Associated News Articles listed on BioPortfolio]

Aerpio Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive Off...

Aerpio Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive O...

Aerpio Pharmaceuticals to Present at the Cowen 38th Annual Health Care Conference

Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that Chief Executive O...

Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference

Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that President and Fou...

Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924

Aerpio Pharmaceuticals (OTCQB:ARPO), today announced the initiation of dosing in a Phase 1a, multiple-ascending dose study of the Company’s hypoxia-inducible factor-1 alpha (HIF-1 alpha) stabilizer,...

Aerpio Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Tuesday, March 13, 2018

Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that its fourth quarter...

Enrollment complete in Aerpio’s phase 2b diabetic retinopathy treatment trial

Aerpio Pharmaceuticals has completed patient enrollment in its phase 2b TIME-2b study of AKB-9778, its treatment candidate for moderate to severe nonproliferative diabetic retinopathy, according to a ...

Aerpio Pharms (ARPO) Presents At LD Micro Virtual Conference 2018 - Slideshow

PubMed Articles [432 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1238 Associated Companies listed on BioPortfolio]

Aerpio Therapeutics

Aerpio Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory bowel ...

Aerpio Therapeutics, Inc.

Aerpio Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on advancing innovative therapies for the treatment of diabetic eye disease and inflammatory b...

Aerpio Pharmaceuticals, Inc.

Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases. The Company’s lead program, AKB‐9778, is ...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Aerpio Therapeutics, Inc." on BioPortfolio

We have published hundreds of Aerpio Therapeutics, Inc. news stories on BioPortfolio along with dozens of Aerpio Therapeutics, Inc. Clinical Trials and PubMed Articles about Aerpio Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Aerpio Therapeutics, Inc. Companies in our database. You can also find out about relevant Aerpio Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...


Corporate Database Quicklinks



Searches Linking to this Company Record